Newsmeme!
Discover News you didn't know existed
First Phase Insulin Release
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
Access Pharmaceuticals initiates Cobalamin technology program for targeted delivery of siRNA therapies
Published February 5, 2010, 1:01 am, News-Medical-Net
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a ...
Biodel Reports First Quarter Fiscal Year 2010 Financial Results
Published February 4, 2010, 1:00 pm, Business Wire via Yahoo! Finance
DANBURY, Conn.----Biodel Inc. today reported financial results for the first fiscal quarter ended December 31, 2009.
Type 1 diabetes: Regeneration exhibits potential as a possible cure
Published February 4, 2010, 12:51 am, News-Medical-Net
A hormone responsible for the body's stress response is also linked to the growth of insulin-producing cells in the pancreas, according to JDRF- funded researchers at the Salk Institute for Biological Studies in California. The findings are the latest advances to underscore the potential for regeneration as a key component of a possible cure for type 1 diabetes.
YOU ARE HERE:
Published February 3, 2010, 8:16 am, Aidsmap
Preliminary results of the study were reported at the 2008 International Conference in Mexico City.
PROLOR Biotech Reports Positive Top-Line Results From Phase I Study Of Its Longer-Acting Version Of Human Growth Hormone
Published February 3, 2010, 6:34 am, Medical News Today
PROLOR Biotech, Inc., (OTC Bulletin Board: PBTH) reported positive top-line results from a Phase I study of its longer-acting version of human growth hormone (hGH). The study was designed to measure the potential durability (half-life), overall drug exposure (AUC) and biological efficacy, as well as the safety and tolerability of PROLOR's longer-acting CTP-modified human growth hormone (hGH-CTP ...
Phosphagenics Announces Positive Results From Phase 1B Study Of Transdermal Oxycodone Patch
Published February 3, 2010, 4:30 am, Medical News Today
Phosphagenics Limited ("Phosphagenics") (ASX: POH; OTCQX: PPGNY) today announced positive results from a Phase 1B clinical study using the Company's patented TPM™ (Targeted Penetration Matrix) for the transdermal delivery of oxycodone. The results of the successful trial demonstrate that daily application of a TPM™ patch delivers therapeutic levels of oxycodone into the blood stream in a ...
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |